This site is intended for healthcare professionals

FDA approves Semglee an insulin glargine injection biosimilar for types 1 and 2 diabetes.- Mylan + Biocon

Read time: 1 mins
Last updated:16th Jun 2020
Published:16th Jun 2020
Condition: Diabetes Types 1 & 2
Type: drug
Register for free exclusive healthcare eLearning resources

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest